{"id":"fda-licensed-nivolumab","safety":{"commonSideEffects":[{"rate":"25-30","effect":"Fatigue"},{"rate":"20-25","effect":"Diarrhea"},{"rate":"15-20","effect":"Nausea"},{"rate":"15-20","effect":"Rash"},{"rate":"3-5","effect":"Immune-mediated pneumonitis"},{"rate":"2-5","effect":"Immune-mediated hepatitis"},{"rate":"2-4","effect":"Immune-mediated colitis"},{"rate":"5-10","effect":"Immune-mediated endocrinopathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nivolumab is a monoclonal antibody that binds to programmed death receptor-1 (PD-1) on T cells, preventing interaction with its ligands (PD-L1 and PD-L2) expressed on tumor cells and immune cells. This blockade releases the 'brakes' on the immune system, restoring T-cell proliferation, activation, and anti-tumor function. By reinvigorating exhausted T cells, nivolumab enables durable anti-tumor immunity.","oneSentence":"Nivolumab blocks the PD-1 checkpoint protein on immune cells, allowing them to recognize and attack cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:20.135Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer"},{"name":"Metastatic melanoma"},{"name":"Advanced renal cell carcinoma"},{"name":"Classical Hodgkin lymphoma"},{"name":"Squamous cell carcinoma of the head and neck"},{"name":"Urothelial carcinoma"},{"name":"Colorectal cancer (microsatellite instability-high or mismatch repair deficient)"}]},"trialDetails":[{"nctId":"NCT05907122","phase":"PHASE3","title":"A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-07-26","conditions":"Melanoma","enrollment":256}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["OPDIVO®"],"phase":"phase_3","status":"active","brandName":"FDA-licensed Nivolumab","genericName":"FDA-licensed Nivolumab","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nivolumab blocks the PD-1 checkpoint protein on immune cells, allowing them to recognize and attack cancer cells. Used for Metastatic non-small cell lung cancer, Metastatic melanoma, Advanced renal cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}